1719 results about "Hematological test" patented technology

The invention discloses a block chain-based blood full-process traceability tracking and safety management system and method, and relates to the technical field of blood management, and the method comprises the steps: distributing an encrypted digital identifier with a timestamp for each blood unit; collecting physical characteristic data of the blood storage environment in real time; dynamically adjusting the state mark of the blood product based on a preset plasma quality evaluation model; a threshold signature technology is adopted to ensure that multiple medical institutions complete blood information verification and sharing on the premise of protecting privacy; when it is monitored that the blood environment parameters exceed a safety threshold value, graded early warning is generated, and an emergency processing flow is started; and establishing a blood circulation whole process auditing tracking system. The system has the advantages that the blood whole-process traceability system based on the block chain is constructed, transparent credible management of the whole life cycle of blood products from collection to use is achieved, the trust and privacy protection problem in multi-mechanism cooperation is solved, and the blood safety management level and the emergency processing efficiency are comprehensively improved.

The invention discloses a reticulocyte recognition and grading system based on a blood smear, and particularly relates to the field of medical cell morphology examination, and the system comprises an image acquisition module, a staining normalization module, an instance segmentation module, an erythrocyte classification module, a reticulocyte grading module and a statistics output module. The image acquisition module adopts an automatic microscope platform to continuously scan the blood smear under a 100-time visual field, acquires a high-quality bright field channel image through an automatic focusing technology, and monitors image definition, contrast and illumination uniformity; the statistical output module is used for calculating the proportion and bluish violet intensity statistics of reticulocytes of each level, and generating a visual quality control result and a diagnostic report; according to the invention, full-automatic processing from samples to reports is realized, interpretability and high classification precision are both considered, subjective difference and omission ratio of manual microscopic examination are significantly reduced, and efficiency and consistency of clinical detection are improved.

The invention discloses a machine learning-based intra-operative bleeding risk prediction method and device for spinal surgery. The machine learning-based intraoperative bleeding risk prediction method for spinal surgery comprises the following steps: acquiring information of a patient to be predicted; obtaining a trained hemorrhage risk prediction model; and inputting the information of the patient to be predicted into the trained massive hemorrhage risk prediction model so as to obtain a prediction result. According to the method, the high-precision prediction model is trained through large-scale patient data (including basic information, operation parameters, blood indexes and the like), so that the accuracy and the stability of intraoperative SBL risk prediction are improved. And a Cell Saver use suggestion based on a risk threshold is provided, and blood resource allocation is optimized. Clinical decision-making efficiency is improved through an automatic tool, blood transfusion related complications (such as infection and immune response) are reduced, and patient prognosis is improved.

The invention discloses a sugar chain marker combination for predicting prognosis of liver cancer transarterial chemoembolization and application of the sugar chain marker combination. The invention discovers and verifies that the combination composed of NA3Fb, NA4Fb and NA4F2b can be used as a novel marker for evaluating TACE treatment reaction and prognosis by analyzing a serum sugar chain map of a liver cancer patient for the first time. Based on the marker combination, a TACE-GT prognosis scoring model and system are established, and the progression risk of a patient within 12 months after a TACE operation can be effectively distinguished by noninvasively detecting the expression levels of three carbohydrate chains in serum of the patient and calculating a specific score. The detection method provided by the invention is based on a blood sample, and has the advantages of noninvasiveness and convenience, and a risk assessment system can provide individualized curative effect prediction and decision support for clinicians before and after TACE treatment, and has important values for realizing precise treatment of liver cancer and improving prognosis of patients.

The invention relates to the technical field of hemodialysis, and discloses a hemodialysis ultrafiltration amount adjusting system based on multi-parameter self-adaptive control, which is used for solving the problem of insufficient prediction and prevention precision of a hemodialysis induced hypotension risk in a traditional system. According to the method, firstly, multi-parameter physiological data of the blood volume, the blood pressure and the ion concentration are synchronously collected in the whole dialysis process, then a physiological state data set is constructed through unified standardization and correlation matching, related change modes of the blood volume and the blood pressure are extracted, and ion deviation is superposed to form comprehensive risk characteristics; the risk characteristics are compared with a preset threshold value through trend analysis, the weight of each risk component is adjusted in a self-adaptive mode, a hypotension risk trend index is generated, the ultrafiltration rate is dynamically adjusted in a graded mode according to the indexes, the indexes are coupled with a real-time physiological data feedback closed loop, and therefore the prediction precision and the regulation and control refinement level of dialysis-induced hypotension are improved.

A blood cell analyzer (100) and a blood cell analysis method (300). The blood cell analysis method (300) comprises: sucking a blood sample to be tested; preparing a first determination sample and obtaining first optical information; preparing a second determination sample and obtaining second optical information; generating a first leukocyte classification scatter diagram and a second leukocyte classification scatter diagram; determining a first counting result of neutrophils of the to-be-detected blood sample based on the first leukocyte classification scatter diagram and the second leukocyte classification scatter diagram; determining an actual distribution area of neutrophils from the first leukocyte classification scatter diagram; based on a reference distribution region of neutrophils of a reference leukocyte classification scatter diagram of the normal blood sample, determining a leaf-division nucleophore distribution region from the actual distribution region; determining a second counting result of the cells falling into the leaf-separating nucleogranulocyte distribution area; and based on the first counting result and the second counting result, determining a counting result of the rod-shaped nuclear granulocytes in the to-be-detected blood sample.

A system and method for continuously monitoring blood wherein the system comprises a sensor unit comprising an inline device fluidically connected a patient via a catheter; a fluidics line configured for passage of a flow of blood of the patient; and one or more sensors configured to measure a plurality of blood analytes from the flow of the blood; a computing unit comprising: a memory; and a processor comprising program instructions, wherein the program instructions, when executed, comprise: receiving blood analyte data corresponding to the plurality of blood analytes; integrating timestamps to the blood analyte data; determining one or more trends associated with the blood analyte data; comparing the one or more trends to predetermined thresholds; and determining a risk prediction of one or more medical complications based on whether the one or more trends meet a condition relative to the predetermined thresholds; and a display unit.

The invention discloses a highly inert Gd-DOTA-based contrast agent with a hydrophobic side chain as well as a preparation method and application of the highly inert Gd-DOTA-based contrast agent, and two novel Gd-DOTA-based contrast agents Gd-L1 and Gd-L2 are successfully developed by respectively connecting hydrophobic 3-phenyl propylamine and 3, 3-diphenyl propylamine to Gd-DOTABA. The two novel Gd-DOTA-based contrast agents remarkably improve the chemical inertness of the complex, the dissociation half-life period of the complex in a 1 M HCl solution at 37 DEG C is about 5 times that of Gd-DOTA, and a powerful guarantee is provided for clinical safety; the MRI (Magnetic Resonance Imaging) performance of the liver in a mouse shows that Gd-L1 is equivalent to commercially available Gd-BOPTA and is suitable for imaging of a liver and gall system; after the Gd-L2 is combined with the human serum albumin, the longitudinal relaxation rate is obviously increased (r1 = 14.8 mM <-1 > s <-1 >, 1.4 T, 37 DEG C), the blood elimination half-life period in a rabbit model is about 18 minutes, and the Gd-L2 is suitable for vascular MRI (Magnetic Resonance Imaging). The two contrast agents avoid the spleen residual problem, the organ accumulation possibility is reduced, and a safer and more efficient MRI diagnostic tool is provided for clinic.

The invention belongs to the field of biological medicine, and discloses a blood marker for identifying epilepsy convulsion and application thereof. The inventor finds that the LRG1 is obviously increased during epileptic convulsion, which indicates that the increase of the blood LRG1 is a blood marker during the acute attack stage of epileptic convulsion. The invention proposes and verifies that the LRG1 is the peripheral blood marker in the acute attack stage of epilepsy convulsion for the first time, and can be used as a clinical auxiliary diagnosis and treatment target.

To enable water removal control that can respond to various patients and the conditions of each patient, and that can perform efficient water removal treatment while reducing the burden on the patient. [Solution] The device has a memory unit that stores the water removal achievement rate at a specified elapsed time during blood purification treatment, and a calculation unit that sets a water removal profile in which the water removal rate gradually decreases from the start to the end of blood purification treatment, and the calculation unit is equipped with a water removal rate determination unit that determines the water removal rate for a specified time at a specified elapsed time based on the water removal achievement rate.

This invention discloses a blood purification device and medical system. The blood purification device includes: a device housing; a blood purifier; a blood tubing assembly, the blood tubing assembly including a first blood tubing connecting a human blood vessel to the inlet of the blood purifier and a second blood tubing connecting the outlet of the blood purifier to the human blood vessel; a power assembly including a blood pump for driving blood flow within the blood tubing assembly, a first replenishment pump for allowing anticoagulant solution to flow into the first blood tubing, and / or a second replenishment pump for allowing calcium solution to flow into the second blood tubing; and a blood component analysis component disposed within the device housing, the blood component analysis component being used to detect collected blood samples. This design facilitates the appropriate adjustment of anticoagulant drugs and calcium ions in the blood purification circuit.

The invention relates to determining blood pressure of a subject based on a pressure signal that has been measured by using a measurement device comprising a) a shell encasing a part of the subject, through which blood flows, b) a pressure applicator applying pressure to the shell and thereby to the encased part of the subject, and c) a pressure sensor measuring the pressure signal on the skin of the encased part of the subject. For several pressure pulses of the pressure signal a respective feature characterizing the respective pressure pulse is determined, wherein based on the respective feature a respective blood pressure determination value is determined, thereby forming a blood pressure determination curve (TPW_M-curve) that is used for determining the blood pressure. This allows to determine the blood pressure with relatively low computational efforts.

An early screening system for chronic obstructive pulmonary disease based on blood routine test data. It belongs to the technical field of digital medical treatment, and specifically relates to the technical field of intelligent early screening of chronic obstructive pulmonary disease. It solves the technical problem that the generalization ability of a COPD prediction model is limited due to differences between different research data sets. The system comprises a data collection module that collects blood routine test data of a plurality of chronic obstructive pulmonary disease patients and blood routine test data of a plurality of normal personnel; a data preprocessing module that performs standardization processing on the blood routine test data to obtain a standardized data set; a screening model training module that trains N classification models using the standardized data set and calculates the prediction accuracy of each classification model; and a screening model application module that obtains the fusion weight of each model by using a normalization processing method based on the prediction accuracy of each classification model, fuses the risk scores predicted by the multiple models, and obtains a final screening result.

The invention discloses a PNA-based pre-targeting probe as well as a preparation method and application thereof. The pre-targeting probe based on the PNA comprises a pre-targeting receptor probe PNA-EB-RGD and a ligand probe cPNA labeled by radionuclide, in the PNA-EB-RGD, the PNA is peptide nucleic acid, the EB is Evans blue, and the RGD is RGD peptide; the cPNA is a complementary sequence of the PNA. The PNA-based pre-targeting probe provided by the invention can reduce systemic circulation radiation exposure, obviously reduce blood toxicity and slow down tumor growth.

The invention relates to the field of medical informatics, and provides a hemodialysis multi-mode risk closed-loop control system. Comprising a multi-source data acquisition module used for acquiring heterogeneous data in a dialysis process in real time; the space-time fusion engine module is used for carrying out space-time alignment and feature extraction of cross-modal data on the heterogeneous data by adopting a graph neural network architecture to generate a fusion feature vector; the dynamic risk prediction module is used for constructing a multi-dimensional risk assessment system based on the fusion feature vector, carrying out probability prediction on multiple risk types and outputting a prediction result; and the intelligent intervention control module evaluates the risk level according to the prediction result output by the dynamic risk prediction module, and generates an intervention strategy through a reinforcement learning algorithm. According to the invention, the timeliness and accuracy of intervention response are improved, and the incidence rate of dialysis complications is reduced.

The invention relates to the technical field of medical equipment, and discloses an intelligent temperature control and flow control system for hemodialysis, which comprises a dialysis pipeline shunting shell; the two main pipelines are arranged in the dialysis pipeline shunting shell, and a plurality of slave pipelines are arranged between the two main pipelines; when the flow rate of the liquid is low, the slave pipeline is far away from the heating component, the temperature of the liquid cannot rise too fast under the condition that the flow rate is low, the knob part can move to the slave pipeline when controlling the valve component to increase the flow rate of the liquid, and the slave pipeline moves close to the heating component. The distance between the auxiliary pipeline and the temperature rising component is reduced, when the flow rate of liquid with large flow is high, the auxiliary pipeline gets close to the temperature rising component, heat generated by the temperature rising component can be better received by the auxiliary pipeline and conducted to the liquid, and the flow adjusting system and the temperature control system can cooperate to achieve the purpose that the flow adjusting system and the temperature control system work together. A preset temperature value can be provided for the dialysis liquid all the time when the flow is increased or decreased.

The invention relates to the crossing field of computer technology and edge calculation, and discloses a blood purification equipment real-time control method based on edge calculation. According to the method, multi-modal real-time physiological parameters, historical dialysis data and a current treatment target are fused through a local edge calculation unit, an individualized body fluid dynamic response prediction model is constructed, and an ultrafiltration rate instruction is optimized and generated within a millisecond level; the system comprises a multi-mode sensor array, a historical data storage module, a task planning interface, an edge computing unit and an ultrafiltration pump controller. According to the application, the hemodynamic state is accurately maintained, the risk of hypotension is remarkably reduced, and the treatment safety and individualization level are improved.

The invention provides a method and a system for predicting early gastric cancer prognosis by a circulating marker, and relates to the technical field of auxiliary diagnosis. The method comprises the following steps: performing multi-omics detection on a blood sample based on a preset sampling time sequence to obtain a multi-dimensional time sequence characteristic data set containing three groups of heterogeneous data of circulating tumor DNA, exosomes and protein markers; calculating a change slope and a fluctuation variance of the heterogeneous data in adjacent time sequence intervals, constructing a dynamic variation feature matrix in combination with a standard attenuation weighting factor, and deeply mining spatial cross-correlation and sequence dependence features of the matrix to generate a multi-modal fusion feature fingerprint; and performing regression operation on the feature fingerprints by using an integrated learning stack model to obtain a dynamic prognosis risk score, and further retrieving a risk hierarchical mapping table to generate a prognosis evaluation result containing a survival curve. According to the method, multi-modal heterogeneous data can be effectively fused, the biological dynamic characteristics in the tumor postoperative recovery phase are captured, and the accuracy and timeliness of early gastric cancer prognosis prediction are remarkably improved.

The invention discloses a sugar chain marker combination for predicting the recurrence risk of a gastric cancer patient after treatment and application of the sugar chain marker combination. The invention discovers that the levels of six specific N-sugar chains (NGA2F, NG1A2F, NA3, NA3Fb, NA4 and NA4Fb) in blood are obviously related to relapse during definite diagnosis of gastric cancer for the first time. On the basis, a gastric cancer recurrence risk prediction model GC-GPSS is constructed through Cox regression. According to the model, individual risk scores are calculated by using a quantification formula containing a fixed regression coefficient (beta), and patients are divided into a high-risk group and a low-risk group according to a preset threshold. A verification result shows that the model can effectively distinguish patient groups with different recurrence risks. The marker combination, the prediction model and the system provided by the invention provide a brand new tool for realizing earlier and more objective recurrence risk assessment in the early stage of gastric cancer diagnosis and treatment, and have important clinical application value.

A microneedle device comprises a device structure, insertable to a living body and being formed with an opened niche at least partially surrounded by walls of micrometric heights above a base of the niche for allowing the niche to be filled with a blood sample upon the insertion. The device also comprises a biosensor configured to sense a bioanalyte in the blood sample and having a sensing element formed on the base. The thickness of the sensing element is less than the micrometric heights of the walls.

The present invention relates to a system and a method for measuring and analyzing minimal residual disease (MRD) in pediatric B-cell precursor acute lymphoblastic leukemia (B-ALL) using multiparameter flow cytometry (MPFC). The invention finds application in clinical diagnostics and hematology-oncology for quantifying MRD in B-ALL patients with high sensitivity and specificity, needed for risk stratification, monitoring treatment response, and informing therapeutic decisions. The system comprises interconnected subsystems including an acquisition subsystem with an MPFC instrument, a control and file generation subsystem, and an analytical subsystem. The analytical subsystem incorporates modules for sequential data reduction, automated data cleaning, automated unsupervised data clustering, and interactive cluster analysis. Key advantages include high MRD detection sensitivity (e.g., 10⁻⁵ or 0.001%) and high specificity, without reliance on reference samples or supervised machine learning models, making it applicable in laboratories with different measuring equipment and using different panels of antibodies for identification of leukemic cells.

The invention discloses a bone defect repair material suitability prediction method based on deep learning, and the method comprises the steps: carrying out the overlapping and uniform partitioning of a bone defect region and a host bone region in three-dimensional CT image data, carrying out the position coding and feature extraction of a plurality of sub-blocks through a three-dimensional visual Transform model of multi-scale position coding, and obtaining the anatomical and functional features; calculating a bone metabolism activity score and a systemic inflammation score based on blood detection data, and then constructing pathophysiological features; performing multi-round interaction on the anatomical and functional features, the pathophysiological features, the parameter data and the multidirectional multi-head cross attention layer, in each round, selecting one modal feature as a query vector, and selecting any modal feature in the rest modal features as a key vector and a value vector; and fusing the interaction features of each round, and determining the suitability score and the risk level of the bone repair material by combining the attention weight and the bone metabolism activity score in the multidirectional multi-head cross attention layer.

The invention discloses an immunosensor for detecting Alzheimer's disease neurofilament light chain protein based on a two-dimensional metal organic framework and a preparation method of the immunosensor, and belongs to the technical field of biological detection sensors. An electrode modified with a RuMOFNSs-Ab2 conjugate and an Au-coated MoS2-Ab1 conjugate is used as a working electrode; the sandwich type electrochemical luminescence immunosensor is based on the two-dimensional RuMOFNSs / Au-coated MoS2, can be used for detecting the blood marker NfL of the Alzheimer's disease, provides a thought for the field of analysis and detection of the NfL, and also provides a reference for clinical medicine detection.

The invention discloses a thrombelastogram calibration method, device, system and equipment and a storage medium, and the method comprises the steps: generating an initial thrombelastogram in a process that a blood sample rotates along with a container, through a mechanical torsion signal which drives a suspension wire to move in and after a process that the blood sample forms a blood clot, and collecting the initial thrombelastogram through a mechanical sensor; the method comprises the following steps: generating a light intensity time change chart through near-infrared light signals collected by a spectrograph, and extracting an attenuation rising rate representing a blood sample coagulation rate, an attenuation value representing blood sample coagulation intensity and an attenuation recovery rate representing fibrinolysis after blood sample coagulation, so as to calibrate an initial thromboelastogram and obtain a calibrated thromboelastogram. Therefore, on the basis of the thrombelastogram measured on the basis of the mechanics principle, the attenuation signal measured by the near-infrared optical principle is utilized to calibrate the thrombelastogram, the influence of non-coagulation factor interference on only mechanical signals is reduced, and the accuracy and the reliability of generating the thrombelastogram are improved.

The utility model discloses a blood detection device. The blood detection device comprises a shell, test paper and a cap, the shell comprises an upper shell and a lower shell which are fixedly connected, a containing cavity is formed between the upper shell and the lower shell, the test paper is located in the containing cavity, a blood sampling head is formed at the front end of the shell, a liquid inlet is formed in the blood sampling head, and the liquid inlet is communicated with the containing cavity through a capillary structure and a premixing cavity in sequence; a hydrophobic coating belt arranged in the left-right direction is arranged on the front cavity wall of the premixing cavity, and an air hole communicated with the containing cavity is formed in the rear end of the shell; the front end of the shell is sleeved with the cap, a liquid storage bag is arranged at the bottom in the cap, and buffer liquid is stored in the liquid storage bag. The blood detection device can realize integration of sample collection and sample treatment, and has the advantages of simple structure, low manufacturing cost, convenience in use, high detection success rate, high detection accuracy and the like.

The utility model relates to the technical field of blood preservation, in particular to a stable preservation liquid device for preserving plasma free DNA for a long time, which comprises a preservation liquid device main body, the upper surface of the preservation liquid device main body is fixedly connected with a supporting material receiving shell, and the inner ring surface of the supporting material receiving shell is fixedly connected with a mounting block. And an extended threaded rod is inserted into the surface of the inner ring of the mounting block in a limiting manner. According to the stable preserving fluid equipment for preserving plasma free DNA for a long time, a preserving test tube can be clamped through a fixing plate, the temperature can be adjusted after ice blocks are added into a supporting material collecting shell, and after the temperature is adjusted, a pull handle needs to be pulled, so that the preserving fluid equipment can be used for preserving plasma free DNA stably. And then a user can take down the piston from the supporting material collecting shell, so that ice blocks in the supporting material collecting shell can be replaced, and the preserving fluid equipment can be conveniently transferred to a site through a plurality of universal wheels fixedly connected to the surface of the bottom of the preserving fluid equipment main body and an operation handrail.

A biological fluid collection system that receives a sample and provides flow-through blood stabilization technology and a precise sample dispensing function for point-of-care and near patient testing applications is disclosed. A biological fluid collection system of the present disclosure is able to effectuate distributed mixing of a sample stabilizer within a blood sample and dispense the stabilized sample in a controlled manner. In this manner, a biological fluid collection system of the present disclosure enables blood micro-sample management, e.g., passive mixing with a sample stabilizer and controlled dispensing, for point-of-care and near patient testing applications.

A capillary blood collection device includes a body having an internal chamber. The body generally includes a first end, a second end, and a port located between the first and second ends and providing an inlet / outlet between the first and second ends to the internal chamber. The first end defines an opening into the internal chamber, and the second end of the body opposite the first end is compressible and configured to generate a vacuum upon compression. The port can receive at least one of a lancet device or a collection tube.